普沙托韦
外观
臨床資料 | |
---|---|
商品名 | Presatovir |
法律規範狀態 | |
法律規範 |
|
识别信息 | |
| |
CAS号 | 1353625-73-6 |
PubChem CID | |
化学信息 | |
化学式 | C24H30ClN7O3S |
摩尔质量 | 532.1 |
3D模型(JSmol) | |
| |
|
普沙托韦(GS-5806,化学式C24H30ClN7O3S)是一种抗病毒药,被开发用于治疗呼吸道合胞病毒感染。它作为一种融合抑制剂,在II期临床试验中显示出较好的疗效。[1][2]
参见
[编辑]参考文献
[编辑]- ^ Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, et al. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract. Clinical Infectious Diseases. December 2019. PMID 31915807. doi:10.1093/cid/ciz1167.
- ^ Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, et al. Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus. The Journal of Infectious Diseases. January 2020. PMID 31971597. doi:10.1093/infdis/jiaa028.